Just before midnight on Thursday, the Food and Drug Administration updated the emergency use authorizations for both the Pfizer/BioNTech and Moderna COVID-19 vaccines, allowing immunocompromised people to receive a third dose of vaccine at least 28 days following the two-dose regimen to further boost protection. The FDA said the change applied specifically to “solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.”
